Literature DB >> 29572681

HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication.

Jonathan Herskovitz1, Howard E Gendelman2,3.   

Abstract

Macrophages serve as host cells, inflammatory disease drivers and drug runners for human immunodeficiency virus infection and treatments. Low-level viral persistence continues in these cells in the absence of macrophage death. However, the cellular microenvironment changes as a consequence of viral infection with aberrant production of pro-inflammatory factors and promotion of oxidative stress. These herald viral spread from macrophages to neighboring CD4+ T cells and end organ damage. Virus replicates in tissue reservoir sites that include the nervous, pulmonary, cardiovascular, gut, and renal organs. However, each of these events are held in check by antiretroviral therapy. A hidden and often overlooked resource of the macrophage rests in its high cytoplasmic nuclear ratios that allow the cell to sense its environment and rid it of the cellular waste products and microbial pathogens it encounters. These phagocytic and intracellular killing sensing mechanisms can also be used in service as macrophages serve as cellular carriage depots for antiretroviral nanoparticles and are able to deliver medicines to infectious disease sites with improved therapeutic outcomes. These undiscovered cellular functions can lead to reductions in persistent infection and may potentially facilitate the eradication of residual virus to eliminate disease.

Entities:  

Keywords:  Cell ontogeny; Human immunodeficiency virus; Long acting slow effective release antiretroviral therapy; Monocyte-derived macrophages; Mononuclear phagocytes; Viral persistence; Viral reservoirs

Year:  2018        PMID: 29572681      PMCID: PMC6501843          DOI: 10.1007/s11481-018-9785-6

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  164 in total

1.  Regulation of Th1/Th2 development by antigen-presenting cells in vivo.

Authors:  M Moser
Journal:  Immunobiology       Date:  2001-12       Impact factor: 3.144

2.  [Pericardial effusions and mediastinal radiotherapy. 4 cases].

Authors:  A Cénac; S Gaudeau; P Vernant
Journal:  Nouv Presse Med       Date:  1975-01-18

3.  Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages.

Authors:  B Lee; M Sharron; L J Montaner; D Weissman; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

4.  Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils.

Authors:  S Struyf; P Menten; J P Lenaerts; W Put; A D'Haese; E De Clercq; D Schols; P Proost; J Van Damme
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

5.  Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia.

Authors:  H Koziel; S Kim; C Reardon; X Li; R Garland; P Pinkston; H Kornfeld
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

6.  The regulation of alpha chemokines during HIV-1 infection and leukocyte activation: relevance for HIV-1-associated dementia.

Authors:  L Poluektova; T Moran; M Zelivyanskaya; S Swindells; H E Gendelman; Y Persidsky
Journal:  J Neuroimmunol       Date:  2001-11-01       Impact factor: 3.478

Review 7.  HIV neuropathy: insights in the pathology of HIV peripheral nerve disease.

Authors:  C A Pardo; J C McArthur; J W Griffin
Journal:  J Peripher Nerv Syst       Date:  2001-03       Impact factor: 3.494

8.  Increased priming for interleukin-12 and tumour necrosis factor alpha in CD64 monocytes in HIV infection: modulation by cytokines and therapy.

Authors:  M Bocchino; E Ledru; T Debord; M L Gougeon
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

9.  Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity.

Authors:  P R Gorry; G Bristol; J A Zack; K Ritola; R Swanstrom; C J Birch; J E Bell; N Bannert; K Crawford; H Wang; D Schols; E De Clercq; K Kunstman; S M Wolinsky; D Gabuzda
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates.

Authors:  S Li; J Juarez; M Alali; D Dwyer; R Collman; A Cunningham; H M Naif
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

View more
  15 in total

Review 1.  Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs.

Authors:  Tiffany A Peterson; Andrew G MacLean
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-13       Impact factor: 4.147

2.  Editor's Commentary for Special Issue: "The Role of Macrophages in HIV Persistence".

Authors:  Tricia H Burdo
Journal:  J Neuroimmune Pharmacol       Date:  2019-02-09       Impact factor: 4.147

3.  Isolation, Transfection, and Culture of Primary Human Monocytes.

Authors:  Karlie Plaisance-Bonstaff; Celeste Faia; Dorota Wyczechowska; Duane Jeansonne; Cecilia Vittori; Francesca Peruzzi
Journal:  J Vis Exp       Date:  2019-12-16       Impact factor: 1.355

Review 4.  The Increase of HIV-1 Infection, Neurocognitive Impairment, and Type 2 Diabetes in The Rio Grande Valley.

Authors:  Roberto De La Garza; Hansapani Rodrigo; Francisco Fernandez; Upal Roy
Journal:  Curr HIV Res       Date:  2019       Impact factor: 1.581

5.  The Neuropeptides Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Control HIV-1 Infection in Macrophages Through Activation of Protein Kinases A and C.

Authors:  Jairo R Temerozo; Suwellen S D de Azevedo; Daniella B R Insuela; Rhaíssa C Vieira; Pedro L C Ferreira; Vinícius F Carvalho; Gonzalo Bello; Dumith Chequer Bou-Habib
Journal:  Front Immunol       Date:  2018-06-12       Impact factor: 7.561

6.  Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice.

Authors:  Prasanta K Dash; Rafal Kaminski; Ramona Bella; Hang Su; Saumi Mathews; Taha M Ahooyi; Chen Chen; Pietro Mancuso; Rahsan Sariyer; Pasquale Ferrante; Martina Donadoni; Jake A Robinson; Brady Sillman; Zhiyi Lin; James R Hilaire; Mary Banoub; Monalisha Elango; Nagsen Gautam; R Lee Mosley; Larisa Y Poluektova; JoEllyn McMillan; Aditya N Bade; Santhi Gorantla; Ilker K Sariyer; Tricia H Burdo; Won-Bin Young; Shohreh Amini; Jennifer Gordon; Jeffrey M Jacobson; Benson Edagwa; Kamel Khalili; Howard E Gendelman
Journal:  Nat Commun       Date:  2019-07-02       Impact factor: 14.919

7.  The Dual-Specificity Kinase DYRK1A Modulates the Levels of Cyclin L2 To Control HIV Replication in Macrophages.

Authors:  Javan K Kisaka; Lee Ratner; George B Kyei
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

Review 8.  Epigenetic Mechanisms of HIV-1 Persistence.

Authors:  Roxane Verdikt; Olivier Hernalsteens; Carine Van Lint
Journal:  Vaccines (Basel)       Date:  2021-05-17

Review 9.  Therapeutic Nanoparticles and Their Targeted Delivery Applications.

Authors:  Abuzer Alp Yetisgin; Sibel Cetinel; Merve Zuvin; Ali Kosar; Ozlem Kutlu
Journal:  Molecules       Date:  2020-05-08       Impact factor: 4.411

Review 10.  Pathways towards human immunodeficiency virus elimination.

Authors:  Prasanta K Dash; Bhavesh D Kevadiya; Hang Su; Mary G Banoub; Howard E Gendelman
Journal:  EBioMedicine       Date:  2020-02-27       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.